GEN Exclusives

More »

GEN News Highlights

Back to Item »

Biovail Licenses Acadia's Late-Stage CNS Disease Drug with an Initial Fee of $30M

Deal is valued at $395 million and allows Biovail to develop the compound in three indications.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?